Press release - 08/10/2026 High iron levels may promote the mobility of brain tumor cells Iron is essential for healthy cells. Cancer cells also require this trace element. Researchers in Freiburg have now found evidence that high levels of iron directly in the tumor microenvironment promote the spread of certain cells in a particularly aggressive type of brain tumor known as glioblastoma. In the long term, iron metabolism could therefore serve as a target for more precisely influencing particularly invasive tumor cells.
Press release - 06/10/2026 EXIST funding for xenko start-up team at Ulm University Virtual health platform to encourage more physical activity in the working day The start-up xenko has been awarded an EXIST grant of 143,500 € from the Federal Ministry for Economic Affairs and Energy. The team of founders from Ulm University is developing a digital health platform designed to encourage more physical activity in everyday working life through virtual reality. This development is of interest to companies with occupational health management schemes and, in the long term, to the physiotherapy sector as well.
Press release - 06/10/2026 Harnessing Synthetic Cellular Systems as Immune Cell Boosters How can cell-based immunotherapies for cancer and autoimmune diseases become more widely available in the long term? The SYNTHIA project is addressing this challenge: The Max Planck Institute for Medical Research and the Fraunhofer Institute for Cell Therapy and Immunology IZI are collaborating on new research approaches to advance the development of cell-based immunotherapies.
Press release - 05/10/2026 A Matter of Quantity: A Universal Target for CAR-T Cells Against Cancer CAR-T cell therapies have proven successful in treating several types of blood and lymphoid cancers. However, their use in treating other tumors is significantly more challenging, in part because suitable target structures are lacking.
Press release - 05/10/2026 A Matter of Quantity: A Universal Target for CAR-T Cells Against Cancer CAR-T cell therapies have proven successful in treating several types of blood and lymphoid cancers. However, their use in treating other tumors is significantly more challenging, in part because suitable target structures are lacking.
Press release - 05/10/2026 How blood flow controls liver function The liver is organized into distinct zones in which liver cells perform different functions. The blood vessels of the liver play an important role in this spatial organization: the endothelial cells lining the vessels provide signals that instruct neighboring liver cells and help determine their function. But how do endothelial cells know which signals to produce?
Press release - 01/10/2026 New AI Agent to Capture and Analyze Patient Experiences for Healthcare Delivery and Health Systems An international consortium led by researchers at the Heidelberg Faculty of Medicine at Heidelberg University will develop an AI-powered interactive assistant for the analysis of patient experiences over the next four years. The goal is to identify individual burdens and challenges early and comprehensively and make this information actionable for patients, care teams, and health systems.
Press release - 30/09/2026 How cells pass on regulatory information A project funded by the Baden-Württemberg Stiftung at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg is investigating the interplay between RNA modifications and epigenetic mechanisms during cell division – and its potential significance for treatment resistance in cancer.
Press release - 25/09/2026 Heidelberg University with Top Placings in latest Shanghai Subject Ranking With clinical medicine and medical technology Heidelberg University is again among the best players in Medical Sciences worldwide. In the Global Ranking of Academic Subjects 2026 clinical medicine rose by one place over last year to rank 17th internationally in clinical medicine and so leads the field in Germany. Medical technology is in 21st place internationally and continues to be ranked third in Germany.
Press release - 24/09/2026 Enzyme Beads for More Sustainable Chemistry Thanks to enzyme-based biocatalysis, an enormous range of pharmaceutical active ingredients and other complex molecules can be synthesized in an environmentally friendly manner. Researchers at the Karlsruhe Institute of Technology (KIT) have now developed a technology that allows to assemble enzymes into millimeter-sized, storable beads. In this process, the enzymes not only act as catalysts but also constitute the beads’ material itself.
Press release - 23/09/2026 ViferaXS Raises €12 Million to Advance Phase II Trial in Chronic Lymphocytic Leukemia and Expand Its Oncology Pipeline ViferaXS, a clinical-stage biotechnology company developing peptide-based cancer immunotherapy for hematologic malignancies and solid tumors, today announced the close of the Series A financing round of up to €12 million, including grant funding. The round was led by SPRIND, the German Federal Agency for Breakthrough Innovation, and Huma, with participation from private investors.
Press release - 17/09/2026 New technique could make MRI more precise A team of researchers at the University of Stuttgart has developed a new method that could make MRI even more precise by eliminating “dead time,” a key limiting factor in the measurement process, thereby enabling the detection of signals that are lost using conventional methods. This method opens up new possibilities for medical diagnostics and non-destructive materials testing. The research team presents the new approach in Science Advances.